Hos de patienter, der opnåede deres første fuldstændige remission, var den gennemsnitlige tid uden sygdom øget fra 291 dage uden behandling til 450 dage efter behandling med Ceplene og interleukin- 2.
The combination of Ceplene and interleukin-2 was more effective than no treatment in increasing the time until AML came back or the patient died: in the patients in their first complete remission, the average time without disease increased from 291 days with no treatment to 450 days after treatment with Ceplene and interleukin-2.